smartbax develops novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms. With the first-in-class compounds, the company targets the multi-drug resistant pathogens methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
Location: Germany
Employees: 1-10
Total raised: $6.79M
Founded date: 2021
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.10.2025 | Seed | $5.5M | Bayern Kap... |
| 25.05.2023 | Seed | $1.29M | - |
Mentions in press and media 9
| Date | Title | Description |
| 24.10.2025 | smartbax Secures €4.7M to Combat Global Antibiotic Resistance Crisis | Munich-based biotech smartbax secured €4.7 million in pre-Series A funding. This capital fuels the fight against antibiotic resistance, a critical global health crisis. Smartbax develops innovative small-molecule antibiotics. Their pipeline... |
| 22.10.2025 | smartbax Raises €4.7M in First Closing of Pre-Series A Funding | smartbax, a Munich, Germany-based biotech company developing next-generation antibiotics against multi-drug resistant bacteria, held the first closing of its €4.7 M Pre-Series A financing round. The round was led by new investors Anobis Ass... |
| 22.10.2025 | smartbax: €4.7 Million Pre-Series A Funding Raised To Advance Antibiotics Against Drug-Resistant Bacteria | smartbax, a biotechnology company pioneering innovative small-molecule antibiotics to combat multidrug-resistant bacteria, announced the first closing of its €4.7 million Pre-Series A financing round. The investment was led by new backers A... |
| 22.10.2025 | smartbax secures €4.7 million as Germany confronts 10,000 deaths a year from drug-resistant infections | smartbax, a Munich-based BioTech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the successful first closing of its €4.7 million pre-Series A financing round. The round was led by new i... |
| 25.05.2023 | smartbax Announces Seed Financing of €1.2 Million to Develop Next-generation Antibiotics | May 23, 2023 |
| 23.05.2023 | smartbax Raises €1.2M in Seed Funding | smartbax, a Munich, Germany-based biotech company developing antibiotics against multi-drug resistant bacteria, raised €1.2M in Seed funding. The round, which brought the total amount to €1.9M, saw participation from Boehringer Ingelheim Ve... |
| 23.05.2023 | m4 Award winner smartbax completes seed funding of EUR 1.2 million to develop innovative antibiotics against multi-resistant bacteria | Munich-based biotech company and m4 Award winner smartbax, which develops next-generation antibiotics, has closed a EUR 1.2 million seed financing round with Boehringer Ingelheim Venture Fund (BIVF) and High-Tech Gründerfonds (HTGF). With t... |
| 07.03.2022 | m4 Award winners on track for success | Three winners of the m4 Award pre-founding competition have been successful. The Munich-based start-ups INVITRIS and Smartbax have received funding as part of INCATE. They want to find solutions against antibiotic resistances that are incre... |
| - | smartbax | “We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.” |